AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

Fri, 08th Apr 2022 11:28

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Journeo PLC, up 35% at 143.04 pence, 12-month range 95.00p-154.00p. The transport system services provider inks a GBP9 million three-year deal with FirstGroup PLC's First Bus UK - its largest agreement to date.

----------

Avacta Group PLC, up 9.9% at 97.77p, 12-month range 38.00p-291.80p. The drug developer and diagnostics company says its joint venture with Daewoong Pharmaceutical Co Ltd called AffyXell Therapeutics has signed a collaboration agreement with Biocytogen, a Chinese company that specialises in biological drugs, and the Korea Non-Clinical Technology Solution Center. The parties will collaborate on new immune disease in vivo models, testing the toxicity of and conducting proof-of-concept for AffyXell's drug candidates, using the developed disease model.

----------

Jet2 PLC, up 4.5% at 1,207.50p, 12-month range 912.40p-1,573.22p. The travel operator says its loss continued to mount in its recently ended financial year, but notes bookings are showing signs of recovery following the dropping of travel restrictions. Jet2 expects a pretax loss before foreign exchange revaluation and tax in its year ended March 31 to come in between GBP378 million and GBP383 million. This would be widened year-on-year from a loss of GBP373.8 million in financial 2021. For financial 2023 so far, Jet2 says summer sale seat capacity is 14% higher than summer of 2019, with an "encouraging" level of bookings.

----------

AIM - LOSERS

----------

Sensyne Health PLC, down 71% at 2.90p, 12-month range 1.00p-178.00p. The clinical artificial intelligence company warns that without further financing it will not be able to continue beyond this month. Sensyne explains it has entered a non-binding term sheet with noteholders to amend the original note purchase agreement to provide an additional GBP15 million in financing. "Shareholders' attention is specifically drawn to the proposed term to cancel the company's shares from trading on AIM and the highly dilutive impact of granting conversion rights to the noteholders and the proposed change in exercise price of the warrants associated with the loan notes," it says. Chief Executive & Founder Paul Drayson steps down from the board with immediate effect. He will be replaced by Alex Snow, former CEO of Landsdowne Partners UK LLP, who has "extensive experience" in finance and the commercialisation of science.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com